Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.

LeWitt PA, Huff FJ, Hauser RA, Chen D, Lissin D, Zomorodi K, Cundy KC.

Mov Disord. 2014 Jan;29(1):75-82. doi: 10.1002/mds.25742. Epub 2013 Dec 13.

PMID:
24339234
2.

Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.

Vakil NB, Huff FJ, Cundy KC.

Aliment Pharmacol Ther. 2013 Jul;38(2):107-17. doi: 10.1111/apt.12363. Epub 2013 May 30.

3.

Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.

Lal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, Cundy KC.

J Clin Pharmacol. 2013 Jan;53(1):29-40. doi: 10.1177/0091270012439209. Epub 2013 Jan 24.

PMID:
23400741
4.

A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome.

Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, Tovera J, Hurt J, Bonzo D, Lassauzet ML, Vu A, Cundy KC.

Clin Neuropharmacol. 2012 Jul-Aug;35(4):165-73. doi: 10.1097/WNF.0b013e318259eac8.

PMID:
22664749
5.

Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.

Lal R, Sukbuntherng J, Luo W, Chen D, Blumenthal R, Ho J, Cundy KC.

Clin Ther. 2012 Jan;34(1):201-13. doi: 10.1016/j.clinthera.2011.12.004. Epub 2011 Dec 28.

PMID:
22206794
6.

Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin.

Backonja MM, Canafax DM, Cundy KC.

Pain Med. 2011 Jul;12(7):1098-108. doi: 10.1111/j.1526-4637.2011.01139.x. Epub 2011 May 31.

PMID:
21627766
7.

A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers.

Lal R, Sukbuntherng J, Ho J, Cundy KC.

Int J Clin Pharmacol Ther. 2011 Feb;49(2):109-15.

PMID:
21255527
8.

Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine.

Lal R, Sukbuntherng J, Luo W, Vicente V, Blumenthal R, Ho J, Cundy KC.

Br J Clin Pharmacol. 2010 May;69(5):498-507. doi: 10.1111/j.1365-2125.2010.03616.x.

9.

The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil.

Lal R, Sukbuntherng J, Luo W, Huff FJ, Zou J, Cundy KC.

Int J Clin Pharmacol Ther. 2010 Feb;48(2):120-8.

PMID:
20137764
10.

Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.

Lal R, Sukbuntherng J, Luo W, Chen D, Vu A, Tovera J, Cundy KC.

Clin Ther. 2009 Aug;31(8):1776-86. doi: 10.1016/j.clinthera.2009.07.026.

PMID:
19808136
11.

Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.

Lal R, Sukbuntherng J, Tai EH, Upadhyay S, Yao F, Warren MS, Luo W, Bu L, Nguyen S, Zamora J, Peng G, Dias T, Bao Y, Ludwikow M, Phan T, Scheuerman RA, Yan H, Gao M, Wu QQ, Annamalai T, Raillard SP, Koller K, Gallop MA, Cundy KC.

J Pharmacol Exp Ther. 2009 Sep;330(3):911-21. doi: 10.1124/jpet.108.149773. Epub 2009 Jun 5.

PMID:
19502531
12.

Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.

Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM.

J Clin Pharmacol. 2008 Dec;48(12):1378-88. doi: 10.1177/0091270008322909. Epub 2008 Sep 30.

PMID:
18827074
13.
14.

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys.

Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA.

J Pharmacol Exp Ther. 2004 Oct;311(1):324-33. Epub 2004 May 14.

PMID:
15146029
15.

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters.

Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA.

J Pharmacol Exp Ther. 2004 Oct;311(1):315-23. Epub 2004 May 14.

PMID:
15146028
16.

Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.

Cullen JM, Li DH, Brown C, Eisenberg EJ, Cundy KC, Wolfe J, Toole J, Gibbs C.

Antimicrob Agents Chemother. 2001 Oct;45(10):2740-5.

17.

Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.

Sweeny DJ, Lynch G, Bidgood AM, Lew W, Wang KY, Cundy KC.

Drug Metab Dispos. 2000 Jul;28(7):737-41.

PMID:
10859145
18.

Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group.

Hughes WT, Shenep JL, Rodman JH, Fridland A, Willoughby R, Blanchard S, Purdue L, Coakley DF, Cundy KC, Culnane M, Zimmer B, Burchett S, Read JS.

Antimicrob Agents Chemother. 2000 Apr;44(4):1041-6.

19.

Aryl ester prodrugs of cyclic HPMPC. I: Physicochemical characterization and in vitro biological stability.

Oliyai R, Shaw JP, Sueoka-Lennen CM, Cundy KC, Arimilli MN, Jones RJ, Lee WA.

Pharm Res. 1999 Nov;16(11):1687-93.

PMID:
10571273
20.

Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.

Cundy KC.

Clin Pharmacokinet. 1999 Feb;36(2):127-43. Review.

PMID:
10092959
21.

Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.

Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT.

Clin Pharmacol Ther. 1999 Jan;65(1):21-8.

PMID:
9951427
22.

Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients.

Cundy KC, Barditch-Crovo P, Petty BG, Ruby A, Redpath M, Jaffe HS, Lietman PS.

Antimicrob Agents Chemother. 1999 Feb;43(2):271-7.

24.

Isolation and identification of a metabolite of cidofovir from rat kidney.

Eisenberg EJ, Lynch GR, Bidgood AM, Krishnamurty K, Cundy KC.

J Pharm Biomed Anal. 1998 Apr;16(8):1349-56.

PMID:
9777608
25.

Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys.

Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC.

Toxicol Sci. 1998 Aug;44(2):97-106.

PMID:
9742650
26.

Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.

Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, Kahn JO.

Antimicrob Agents Chemother. 1998 Sep;42(9):2380-4.

27.

Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.

Van Rompay KK, Marthas ML, Lifson JD, Berardi CJ, Vasquez GM, Agatep E, Dehqanzada ZA, Cundy KC, Bischofberger N, Pedersen NC.

AIDS Res Hum Retroviruses. 1998 Jun 10;14(9):761-73.

PMID:
9643376
28.

Intravitreal and plasma cidofovir concentrations after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis.

Taskintuna I, Rahhal FM, Capparelli EV, Cundy KC, Freeman WR.

J Ocul Pharmacol Ther. 1998 Apr;14(2):147-51.

PMID:
9572540
29.
30.

Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.

Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB.

Antimicrob Agents Chemother. 1998 Mar;42(3):647-53.

31.

Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.

Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, Cundy KC.

Pharm Res. 1997 Dec;14(12):1824-9.

PMID:
9453075
32.

Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs.

Cundy KC, Sue IL, Visor GC, Marshburn J, Nakamura C, Lee WA, Shaw JP.

J Pharm Sci. 1997 Dec;86(12):1334-8.

PMID:
9423141
34.
35.

Bioavailability and metabolism of cidofovir following topical administration to rabbits.

Cundy KC, Lynch G, Lee WA.

Antiviral Res. 1997 Jul;35(2):113-22.

PMID:
9217248
36.

Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats.

Shaw JP, Louie MS, Krishnamurthy VV, Arimilli MN, Jones RJ, Bidgood AM, Lee WA, Cundy KC.

Drug Metab Dispos. 1997 Mar;25(3):362-6.

PMID:
9172955
37.

New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.

Kim CU, McGee LR, Krawczyk SH, Harwood E, Harada Y, Swaminathan S, Bischofberger N, Chen MS, Cherrington JM, Xiong SF, Griffin L, Cundy KC, Lee A, Yu B, Gulnik S, Erickson JW.

J Med Chem. 1996 Aug 30;39(18):3431-4. No abstract available.

PMID:
8784440
38.

Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats.

Cundy KC, Bidgood AM, Lynch G, Shaw JP, Griffin L, Lee WA.

Drug Metab Dispos. 1996 Jul;24(7):745-52.

PMID:
8818571
39.

Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug.

Cundy KC, Li ZH, Hitchcock MJ, Lee WA.

Drug Metab Dispos. 1996 Jul;24(7):738-44.

PMID:
8818570
40.

Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits.

Cundy KC, Lynch G, Shaw JP, Hitchcock MJ, Lee WA.

Curr Eye Res. 1996 May;15(5):569-76.

PMID:
8670758
42.

Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits.

Cundy KC, Li ZH, Lee WA.

Drug Metab Dispos. 1996 Mar;24(3):315-21.

PMID:
8820422
43.

Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects.

Wachsman M, Petty BG, Cundy KC, Jaffe HS, Fisher PE, Pastelak A, Lietman PS.

Antiviral Res. 1996 Mar;29(2-3):153-61.

PMID:
8739595
44.

A novel oligodeoxynucleotide inhibitor of thrombin. II. Pharmacokinetics in the cynomolgus monkey.

Lee WA, Fishback JA, Shaw JP, Bock LC, Griffin LC, Cundy KC.

Pharm Res. 1995 Dec;12(12):1943-7.

PMID:
8786970
45.

A novel oligodeoxynucleotide inhibitor of thrombin. I. In vitro metabolic stability in plasma and serum.

Shaw JP, Fishback JA, Cundy KC, Lee WA.

Pharm Res. 1995 Dec;12(12):1937-42.

PMID:
8786969
46.

Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.

Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, Jaffe HS.

Antimicrob Agents Chemother. 1995 Nov;39(11):2401-5.

47.

Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.

Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJ, Jaffe HS.

Antimicrob Agents Chemother. 1995 Jun;39(6):1247-52.

48.

1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo.

Bischofberger N, Hitchcock MJ, Chen MS, Barkhimer DB, Cundy KC, Kent KM, Lacy SA, Lee WA, Li ZH, Mendel DB, et al.

Antimicrob Agents Chemother. 1994 Oct;38(10):2387-91.

Supplemental Content

Loading ...
Support Center